1. Home
  2. BRBI vs IVVD Comparison

BRBI vs IVVD Comparison

Compare BRBI & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BRBI

BRBI BR Partners S.A. ADSs

N/A

Current Price

$16.32

Market Cap

383.0M

Sector

Finance

ML Signal

N/A

Logo Invivyd Inc.

IVVD

Invivyd Inc.

HOLD

Current Price

$1.60

Market Cap

437.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRBI
IVVD
Founded
2009
2020
Country
Brazil
United States
Employees
188
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
383.0M
437.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
BRBI
IVVD
Price
$16.32
$1.60
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$8.75
AVG Volume (30 Days)
1.8K
3.6M
Earning Date
05-08-2026
05-14-2026
Dividend Yield
4.52%
N/A
EPS Growth
N/A
79.02
EPS
N/A
N/A
Revenue
N/A
$53,426,000.00
Revenue This Year
N/A
$147.67
Revenue Next Year
$17.24
$22.76
P/E Ratio
$11.72
N/A
Revenue Growth
N/A
110.47
52 Week Low
$12.54
$0.46
52 Week High
$67.01
$3.07

Technical Indicators

Market Signals
Indicator
BRBI
IVVD
Relative Strength Index (RSI) 64.70 53.06
Support Level $13.77 $1.41
Resistance Level $16.46 $1.77
Average True Range (ATR) 0.19 0.15
MACD 0.21 0.05
Stochastic Oscillator 97.48 71.43

Price Performance

Historical Comparison
BRBI
IVVD

About BRBI BRBI BR Partners S.A. ADSs

BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered.

About IVVD Invivyd Inc.

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Share on Social Networks: